D. Berd

D. Leeper, R. Coss, M. Wahl, 2004, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.

D. Berd, M. Mastrangelo, D. Berd, 1988, Cancer research.

Deletion mapping of chromosome region 9p21‐p22 surrounding the CDKN2 locus in melanoma

C. Shields, C. Croce, K. Huebner, 1996, International journal of cancer.

A randomized study of methanol-extraction residue of bacille Calmette-Guerin as postsurgical adjuvant therapy of uveal melanoma.

M. Grever, F. Davidorf, J. Gamel, 1990, American journal of ophthalmology.

Autologous, hapten-modified vaccine as a treatment for human cancers.

C. Dunton, H. Maguire, Takami Sato, 1998, Vaccine.

Combination therapy for diffuse histiocytic lymphoma that includes antimetabolites.

J. Bertino, D. Berd, E. Cadman, 1977, Cancer treatment reports.

Treatment of metastatic melanoma with autologous, hapten‐modified melanoma vaccine: Regression of pulmonary metastases

H. Maguire, Takami Sato, D. Berd, 2001 .

Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases.

H. Maguire, Takami Sato, D. Berd, 2001, International journal of cancer.

Acute extracellular acidification increases nuclear associated protein levels in human melanoma cells during 42°C hyperthermia and enhances cell killing

D. Leeper, R. Coss, M. Wahl, 2002, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Whole cell ELISA for detection of tumor antigen expression in tumor samples.

D. Berd, L. Erdile, D. Smith, 2001, Journal of immunological methods.

Growth and metastasis of fresh human melanoma tissue in mice with severe combined immunodeficiency.

G. Murphy, R. Korngold, P. McCue, 1991, Cancer research.

Depletion of T-cells with the CD4+CD45R+ phenotype in lymphocytes that infiltrate subcutaneous metastases of human melanoma.

D. Berd, M. Mastrangelo, G. Cardi, 1989, Cancer research.

Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.

D. Berd, M. Mastrangelo, 1988, Cancer investigation.

Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine

G. Murphy, H. Maguire, D. Berd, 1994, Cancer Immunology, Immunotherapy.

Depletion of suppressor-cytotoxic T-lymphocytes by administration of a murine monoclonal antibody.

D. Berd, M. Mastrangelo, 1987, Cancer research.

Whipsaw cancer treatments: the role of hormesis in endocrine and immune therapies.

D. Berd, R. Prehn, 2006, Seminars in oncology.

Variability in glucose transporter-1 levels and hexokinase activity in human melanoma

A. Bhala, D. Leeper, R. Coss, 2002, Melanoma research.

Commentary (Berd)—Melanoma Vaccines: What We Know So Far

D. Berd, 2005 .

Evaluation of a "nude" mouse-human tumor panel as a predictive secondary screen for cancer chemotherapeutic agents.

D. Berd, M. Mastrangelo, R. Bellet, 1979, Journal of the National Cancer Institute.

Regulation of intracellular pH in human melanoma: potential therapeutic implications.

U. Rodeck, R. Burd, D. Leeper, 2002, Molecular cancer therapeutics.

Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.

C. Farina, G. Nicolini, A. Anichini, 1997, The Journal of clinical investigation.

Newer immunologic approaches to the treatment of patients with melanoma.

D. Berd, M. Mastrangelo, S. Schultz, 1988, Seminars in oncology.

Metastatic uveal melanoma. Hepatic cell-surface enzymes, isoenzymes, and serum sialic acid levels in early metastatic disease.

J. Shields, J. Augsburger, D. Berd, 1983, Archives of ophthalmology.

Phase I study of R24 in patients with metastatic melanoma including evaluation of immunologic parameters.

P. Chapman, P. McCue, H. Maguire, 1998, Cancer biotherapy & radiopharmaceuticals.

Intracellular acidification abrogates the heat shock response and compromises survival of human melanoma cells.

C. Daskalakis, R. Coss, M. Wahl, 2003, Molecular cancer therapeutics.

Metastatic Uveal Melanoma: Pretherapy Serum Liver Enzyme and Liver Scan Abnormalities

L. Donoso, J. Shields, J. Augsburger, 1985 .

Combination chemotherapy of metastatic melanoma.

D. Berd, M. Mastrangelo, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CRITICAL REVIEW OF PREVIOUSLY REPORTED CLINICAL TRIALS OF CANCER IMMUNOTHERAPY WITH NON‐SPECIFIC IMMUNOSTIMULANTS *

D. Berd, M. Mastrangelo, R. Bellet, 1976, Annals of the New York Academy of Sciences.

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

P. McCue, H. Maguire, D. Berd, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Current condition and prognosis of tumor immunotherapy: a second opinion.

H. Maguire, D. Berd, M. Mastrangelo, 1984, Cancer treatment reports.

Augmentation of the human immune response by cyclophosphamide.

P. Engstrom, H. Maguire, D. Berd, 1982, Cancer research.

Chemoimmunotherapy increases the lymphocyte reactivity of melanoma patients.

D. Berd, M. Mastrangelo, R. Bellet, 1979, European journal of cancer.

Differential sensitivity of two murine leukaemia sublines to cytolysis by Corynebacterium parvum-activated macrophages.

D. Berd, M. Mastrangelo, 1981, British Journal of Cancer.

Hapten-Modified Tumor Vaccines

D. Berd, 2004 .

Is human aging still mysterious enough to be left only to scientists?

Gregory Stock, C. Heward, G. Pawelec, 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: relevance to immunologic regression and immunotherapy.

G. Murphy, D. Berd, A. Radu, 1993, The Journal of investigative dermatology.

A phase III comparison of methyl-CCNU + vincristine with or without BCG + allogeneic tumor cells in metastatic melanoma

D. Berd, M. Mastrangelo, R. Bellet, 1979, Cancer Immunology, Immunotherapy.

Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination.

C. Farina, A. Anichini, G. Parmiani, 1998, Journal of immunotherapy.

Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer.

H. Maguire, D. Berd, M. Mastrangelo, 1984, Cancer research.

Fc-receptor for mouse IgG1 (Fc gamma RII) and antibody-mediated cell clearance in patients treated with Leu2a antibody.

R. Colvin, T. Reichert, F. Preffer, 1989, Transplantation.

M-Vax: an autologous, hapten-modified vaccine for human cancer

D. Berd, 2004, Expert review of vaccines.

Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases.

G. Murphy, H. Maguire, G. Murphy, 1991, Cancer research.

Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.

H. Maguire, Takami Sato, D. Berd, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Flow cytometric determination of the frequency and heterogeneity of expression of human melanoma-associated antigens.

M. Herlyn, H. Koprowski, D. Berd, 1989, Cancer research.

Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials

D. Berd, M. Mastrangelo, R. Bellet, 1992, International journal of cancer.

Effect of 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea adjuvant therapy on the immune response of patients with malignant melanoma.

E. J. Wilson, D. Berd, M. Mastrangelo, 1979, Cancer research.

Time to recurrence varies inversely with thickness in clinical stage 1 cutaneous melanoma.

Vincent Miller, D. Berd, M. Mastrangelo, 1990, Surgery, gynecology & obstetrics.

Effects of anticancer drugs on the immune system in humans.

M. J. Ehrke, D. Berd, M. Mastrangelo, 1989, Seminars in oncology.

The immunoaugmenting effects of cancer chemotherapeutic agents.

H. Maguire, D. Berd, M. Mastrangelo, 1986, Seminars in oncology.

Cancer vaccines: reborn or just recycled?

D. Berd, 1998, Seminars in oncology.

Melanomas Abnormal Expression of Perlecan Proteoglycan in Metastatic Updated

R. Iozzo, I. Cohen, D. Berd, 2006 .

Inducing Immunity to Human Melanoma Cells: Opening the Bag of Immunological Tricks

D. Berd, 1992 .

Low doses of chemotherapy to inhibit suppressor T cells.

D. Berd, 1989, Progress in clinical and biological research.

“Autoregulation” of Human Neutrophil Activation In Vitro: Regulation of Phorbol Myristate Acetate‐Induced Neutrophil Activation by Cell Density

S. Peters, K. Albertine, M. Gee, 1990, Journal of leukocyte biology.

Detection of specific genetic alterations in cancer cells.

K. Huebner, J. Lubiński, D. Berd, 1996, Seminars in Oncology.

Autologous, hapten-modified vaccine as a treatment for human cancers.

C. Dunton, H. Maguire, D. Berd, 1998, Seminars in Oncology.

The Dartmouth Regimen: gone or going strong?

D. Berd, M. Mastrangelo, E. McClay, 1998, Cancer investigation.

Commentary (Mastrangelo/Berd): Systemic Treatments for Advanced Cutaneous Melanoma

D. Berd, Mastrangelo Mj, 1995 .